Reviewing Tocagen Inc. (TOCA)’s and HOOKIPA Pharma Inc. (NASDAQ:HOOK)’s results

Tocagen Inc. (NASDAQ:TOCA) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 1 0.00 22.32M -2.53 0.00
HOOKIPA Pharma Inc. 8 0.82 8.21M -22.38 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Tocagen Inc. 3,511,642,542.48% -108.1% -56.6%
HOOKIPA Pharma Inc. 98,796,630.57% 0% 0%

Liquidity

Tocagen Inc. has a Current Ratio of 5 and a Quick Ratio of 5. Competitively, HOOKIPA Pharma Inc.’s Current Ratio is 5.6 and has 5.6 Quick Ratio. HOOKIPA Pharma Inc.’s better ability to pay short and long-term obligations than Tocagen Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Tocagen Inc. and HOOKIPA Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Tocagen Inc. 0 2 0 2.00
HOOKIPA Pharma Inc. 0 0 2 3.00

The average target price of Tocagen Inc. is $1, with potential upside of 57.48%. Meanwhile, HOOKIPA Pharma Inc.’s average target price is $14.5, while its potential upside is 53.28%. The information presented earlier suggests that Tocagen Inc. looks more robust than HOOKIPA Pharma Inc. as far as analyst view.

Insider & Institutional Ownership

Tocagen Inc. and HOOKIPA Pharma Inc. has shares held by institutional investors as follows: 36.1% and 35.9%. Tocagen Inc.’s share held by insiders are 1.8%. On the other hand, insiders held about 0.9% of HOOKIPA Pharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. -5.84% -17% -45.44% -51.06% -39.2% -35.2%
HOOKIPA Pharma Inc. 1.53% 8.32% -47.93% 0% 0% -47.93%

For the past year Tocagen Inc. was less bearish than HOOKIPA Pharma Inc.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.